| Title |
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
|
|---|---|
| Published in |
OncoTargets and therapy, November 2011
|
| DOI | 10.2147/ott.s16392 |
| Pubmed ID | |
| Authors |
Eva Muñoz-Couselo, José Pérez-García, Javier Cortés |
| Abstract |
Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient's duration and quality of life. Treatment options for MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, including trastuzumab and bevacizumab, have further enhanced the landscape of therapeutic options. Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor, and a structurally simplified synthetic analog of the natural marine product, halichondrin B, with a novel mechanism of action that has shown antitumor activity in pretreated MBC. Eribulin has shown a manageable tolerability profile in Phase I-II clinical trials and an improvement in overall survival compared with treatment of physician's choice, without relevant toxicities in a recently published Phase III trial. This review will focus on eribulin as a new active agent for MBC and its role in the management of breast disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 15 | 35% |
| Researcher | 9 | 21% |
| Student > Ph. D. Student | 6 | 14% |
| Student > Bachelor | 4 | 9% |
| Student > Master | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 5 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 42% |
| Chemistry | 4 | 9% |
| Agricultural and Biological Sciences | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 5 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2011.
All research outputs
#23,154,082
of 25,806,080 outputs
Outputs from OncoTargets and therapy
#2,098
of 3,016 outputs
Outputs of similar age
#142,658
of 154,921 outputs
Outputs of similar age from OncoTargets and therapy
#2
of 2 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,921 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.